Abstract
When Stephen O'Brien quickly put together a powerful analysis of the link between genetic mutations and susceptibility to HIV infection, he set off a flap among some colleagues and competitors. O'Brien analyzed DNA from cell lines he had established from large numbers of blood samples provided by other investigators, some of whom say they were not aware of the study until a draft manuscript was circulated. Others complained that his readyaccess to the cell lines gave him an unfair advantage. O'Brien, who included as co-authors those who provided samples, says the work was covered by collaborative agreements. Theflap highlights an issue that is becoming increasingly important in biomedical research: Who should control research on scarce samples?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
